Enanta Pharmaceuticals (ENTA) Current Assets (2012 - 2026)

Enanta Pharmaceuticals' Current Assets history runs 15 years deep, the most recent figure standing at $178.4 million for Q1 2026.

• Quarterly Current Assets fell 26.54% year-over-year to $178.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.4 million (down 26.54% YoY) and the FY2025 annual result came in at $204.3 million, down 31.85% from the prior year.
• Current Assets was $178.4 million for Q1 2026 at Enanta Pharmaceuticals, down from $198.7 million in the prior quarter.
• Across five years, Current Assets topped out at $448.5 million in Q2 2023 and bottomed at $178.4 million in Q1 2026.
• A 5-year average of $296.2 million and a median of $286.6 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets surged 43.26% — and 2024, when it plunged 36.1%.
• Enanta Pharmaceuticals' Current Assets stood at $283.7 million in 2022, then surged by 37.57% to $390.3 million in 2023, then plunged by 31.3% to $268.1 million in 2024, then decreased by 25.9% to $198.7 million in 2025, then retreated by 10.2% to $178.4 million in 2026.
• Business Quant data shows ENTA's Current Assets at $178.4 million in Q1 2026, $198.7 million in Q4 2025, and $204.3 million in Q3 2025.